Breaking News, Collaborations & Alliances

Lonza, Citryll Enter Manufacturing Partnership

Lonza to supply final drug product in finished format for Citryll’s clinical studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Netherlands-based biotech Citryll and contract development and manufacturing organization (CDMO) Lonza have entered a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. CIT-013 targets Neutrophil Extracellular Trap (NET) biology, and could offer new treatment options for a range of diseases where NETs play a role in disease pathology including autoimmune diseases like lupus, rheumatoid arthritis, vasculitis and others.   By targeting NET formation and NETs...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters